It is with great pleasure that we announce that the Ludwig Institute for Cancer Research has established the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine’s Sandra and Edward Meyer Cancer Center.

In a prospective imaging study of 200 adults with lung cancer, photon-counting CT reduced radiation exposure, had fewer adverse reactions and provided higher image quality and better detection of malignant features compared with conventional CT.

People with ulcerative proctitis, a milder and more limited form of ulcerative colitis, are not at higher risk of developing rectal cancer than the general population. This is shown in a new Swedish registry study from Karolinska Institutet, published in Gastroenterology. The findings may contribute to more individualized follow-up of patients with inflammatory bowel disease.

A new study by cell biologists at the University of California, Santa Cruz, in Nature Communications suggests that an early first pregnancy may protect against breast cancer decades later by preventing age-related changes in breast cells that are linked to tumor formation. Using a mouse model designed to mimic human aging and reproductive history, researchers found that pregnancy fundamentally alters how mammary tissue ages—reducing the buildup of abnormal cells that have the ability to change their identity in a way that could seed cancer in later life.

Current drugs for pancreatic cancer lose effectiveness within months because the tumour becomes resistant. The group from Spain’s National Cancer Research Centre (CNIO) has been able to avoid the development of resistance in animal models with a combined triple therapy.

 

These results “pave the way for the design of combined therapies that may improve survival,” the authors indicate, although this will not happen in the short term. The results are published in PNAS.

 

Mariano Barbacid, head of the Experimental Oncology Group at CNIO, emphasises that “we are not yet in a position to carry out clinical trials with this triple therapy.”

New study reveals a central role of GXYLT2 in Wnt/β-catenin–mediated progression of diffuse-type gastric cancer

Gastric cancer (GC) is a highly heterogeneous malignancy with substantial variability in clinical outcomes, particularly between intestinal and diffuse subtypes. Despite advances in molecular profiling, reliable biomarkers that both stratify prognosis and illuminate actionable mechanisms remain limited. Increasing evidence suggests that aberrant glycosylation contributes to tumor progression, yet the clinical and functional relevance of glycosyltransferases in gastric cancer remains incompletely defined.

Colorectal cancer (CRC) is a prevalent malignancy worldwide, characterized by a propensity to metastasize to the liver — a condition known as colorectal cancer liver metastasis (CRLM). Patients with CRLM have a poor prognosis, with a five-year survival rate ranging from 12% to 30%. Since aberrant Wnt signaling is a hallmark of metastatic cancers, elucidating its activation mechanisms and therapeutic targets may provide an effective strategy for treating these high-risk cancers